About Kryptos Biotechnologies
Kryptos Biotechnologies is a company based in Hayward (United States) founded in 2017 by Jinyong Lee and Jun Ho Son. Kryptos Biotechnologies has raised $12.7 million across 3 funding rounds from investors including HHS, OSANG Healthcare and FuturePlay. Kryptos Biotechnologies offers products and services including Infectious Disease Diagnostics and Life Science Solutions. Kryptos Biotechnologies operates in a competitive market with competitors including Inflammatix, Karius, MeMed, Visby Medical and NeuMoDx, among others.
- Headquarter Hayward, United States
- Founders Jinyong Lee, Jun Ho Son
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Kryptos Biotechnologies, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$12.7 M (USD)
in 3 rounds
-
Latest Funding Round
$10 M (USD), Series A
Mar 28, 2024
-
Investors
HHS
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kryptos Biotechnologies
Kryptos Biotechnologies offers a comprehensive portfolio of products and services, including Infectious Disease Diagnostics and Life Science Solutions.
Offers PCR-based testing for point-of-care infectious disease detection.
Provides innovative analytical systems for healthcare and scientific applications.
People of Kryptos Biotechnologies
Unlock access to complete
Unlock access to complete
Funding Insights of Kryptos Biotechnologies
Kryptos Biotechnologies has successfully raised a total of $12.7M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kryptos Biotechnologies
Kryptos Biotechnologies has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, OSANG Healthcare and FuturePlay.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
FuturePlay is engaged in startup investment and acceleration.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Offers financial services including auto loans, corporate finance, and investments to customers.
|
Locked | Locked | Locked |
Investor details for Kryptos Biotechnologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kryptos Biotechnologies
Investment portfolio details for Kryptos Biotechnologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kryptos Biotechnologies
Detailed financials for Kryptos Biotechnologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kryptos Biotechnologies Comparisons
Peer comparison for Kryptos Biotechnologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kryptos Biotechnologies
Kryptos Biotechnologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Karius, MeMed, Visby Medical and NeuMoDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Developer of a non-invasive pathogen blood test for the detection of infectious diseases
|
|
| Locked | Locked | Locked |
Provider of machine learning based diagnostic solutions for infectious diseases
|
|
| Locked | Locked | Locked |
Portable PCR diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
Instruments and test panels for multiplexed molecular diagnostics are provided.
|
Detailed competitors of Kryptos Biotechnologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kryptos Biotechnologies
Complete news archive for Kryptos Biotechnologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kryptos Biotechnologies
Kryptos Biotechnologies was founded in 2017.
Kryptos Biotechnologies is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Jun Ho Son is the current CEO of Kryptos Biotechnologies. They have also founded this company.
Kryptos Biotechnologies is a funded company, having raised a total of $12.7M across 3 funding rounds to date.
Kryptos Biotechnologies was founded in 2017 and is based in Hayward, United States. Operations focus on the biotechnology sector, where a point-of-care molecular diagnostic platform is developed and provided. The platform relies on Ultrafast Photonic PCR, which employs photothermal heating through plasmonic thin films driven by light-emitting diodes. Applications include diagnostics for infectious diseases, cardiac conditions, cancer, neurological disorders, and biowarfare pathogen detection at the point-of-care.
Kryptos Biotechnologies's top competitors include Visby Medical, Inflammatix and MeMed.
Kryptos Biotechnologies offers Infectious Disease Diagnostics and Life Science Solutions.
Kryptos Biotechnologies has 5 investors. Key investors include HHS, OSANG Healthcare, FuturePlay, Coolidge Corner Investment, and KBD Capital.